| Literature DB >> 26866024 |
Abstract
PURPOSE: Atherosclerosis is classically defined as an immune-mediated disease characterized by accumulation of low-density lipoprotein cholesterol over intima in medium sized and large arteries. Recent studies have demonstrated that both innate and adaptive immune responses are involved in atherosclerosis. In addition, experimental and human models have recognized many autoantigens in pathophysiology of this disease. Oxidized low-density lipoproteins, β2 glycoprotein I (β-2-GPI), and heat shock protein 60 (HSP60) are the best studied of them which can represent promising approach to design worthwhile vaccines for modulation of atherosclerosis.Entities:
Keywords: Apolipoprotein B-100; Atherosclerosis; Beta 2-glycoprotein I; HSP60; Vaccine
Year: 2016 PMID: 26866024 PMCID: PMC4742599 DOI: 10.7774/cevr.2016.5.1.50
Source DB: PubMed Journal: Clin Exp Vaccine Res ISSN: 2287-3651
ApoB-100 peptide sequences used for modulating lipoprotein autoimmunity in atherosclerosis
| ApoB-100 peptide | Amino acid No. | Sequence | Ref |
|---|---|---|---|
| p2 | 16-35 | ATRFK HLRKY TYNYE AESSS | [ |
| p45 | 661-680 | IEIGL EGKGF EPTLE ALFGK | [ |
| p210 | 3,136-3,155 | KTTKQ SFDLS VKAQY KKNKH | [ |
Fig. 1Schematic representation of chimeric construct consists of heat shock protein 60 (HSP 60), ApoB-100, and β2 glycoprotein I (β-2-GPI) genes bound together by appropriate linkers for expression in Escherichia coli. It is important to emphasize that ApoB-100 peptides were applied as an appropriate linker as well as immunogenic epitopes in our chimeric construct.
Fig. 2Graphical view of codon usage in optimized chimeric gene (A) and wild type (B).
Fig. 3Prediction of RNA secondary structure of chimeric gene by mofld server. Predicted structure has no hairpin and pseudo knot at 5' site of mRNA.
Free energy details related to 5' end of chimeric gene mRNA structure by mfold web server
| Structural element | Free energy (kcal/mol) | Base pair |
|---|---|---|
| External loop | -0.6 | 9 ss bases and 1 closing helices |
| Stack | -2.1 | External closing pair: U2-A1756 |
| Stack | -2.4 | External closing pair: G3-C1755 |
| Stack | -2.2 | External closing pair: A4-U1754 |
| Helix | -6.7 | 4 Base pairs |
Fig. 4Graphical results for secondary structure prediction of chimeric protein. Purple, red, and blue colors indicate extended strand, coil, and helix, respectively.
Percentage of secondary structure elements of chimeric and single proteins
| Sequence | Alpha helix | Extended strand | Random coil |
|---|---|---|---|
| HSP60 | 41.86 | 14.29 | 43.85 |
| ApoB-100 | 30.00 | 20.00 | 50.00 |
| β-2-GPI | 3.52 | 26.87 | 69.60 |
| Chimeric gene | 29.08 | 17.18 | 53.74 |
Values are presented as percentage.
HSP60, heat shock protein 60; β-2-GPI, β2 glycoprotein I.
Fig. 5Predicted structure of constructed protein using I-TASSER software. The three-dimensional structure generated by I-TASSER software showed a protein with three main domains linked together with appropriated linkers. HSP60, heat shock protein 60; β-2-GPI, β2 glycoprotein I.
Fig. 6Validation of protein structure by Ramachandran plot.
B-Cell epitopes from full length proteins using Bcepred
| Rank | Sequence | Start position | Score |
|---|---|---|---|
| 1 | YTTFEYPNTISFSCNT | 458 | 0.95 |
| 2 | DGTIEVPKCFKEHSSL | 560 | 0.94 |
| 2 | VVAVKAPGFGDNRKNQ | 238 | 0.94 |
| 3 | GGGGSSCKVPVKKATV | 501 | 0.93 |
| 4 | MTVIIEQSWGSPKVTK | 1 | 0.92 |
| 5 | AKSIDLKDKYKNIGAK | 22 | 0.91 |
| 6 | HVAIAGRTCPKPDDLP | 376 | 0.90 |
| 7 | YKNIGAKLVQDVANNT | 31 | 0.89 |
| 8 | ELEIIEGMKFDRGYIS | 151 | 0.89 |
Epitopes predicted in chimeric protein by different parameters based on Bcepred software
| Prediction parameter | Epitope sequence |
|---|---|
| Hydrophilicity | SPKVTKD, QDVANNTNEEAGDGTTTAT, SANGDKEIGN, TVKDGKTLNDE, NTSKGQKCE, AEDVDGEA, GDNRKNQ, EDVQPHD, NYEAESSSKTTKQS, TCPKPDD, NGADSAKCTEEGK, APGGGGSSCK, CKNKEKKCSYTEDAQ, KTDASDVKP |
| Flexibility | DVANNTN, EGFEKISKGA, VIAELKKQS, ATISANG, DAMKKVGR, YFINTSKGQK, VLLSEKKI, PGFGDNRKNQ, YNYEAESSSKTTK, GYVSRGGM, VCAPGGGGSS, KIQEKFK, SFFCKNKEKK |
| Accessibility | QSWGSPKVTKDG, KSIDLKDKYKNIGAK, QDVANNTNEEAGD, AKEGFEKI, NPVEIRR, IAELKKQSKPVTTPEEIAQ, SANGDKE, MKKVGRKG, TVKDGKTLNDEL, EGMKFDRGY, INTSKGQKCEFQD, LSEKKISS, ANAHRKPL, GFGDNRKNQLKDM, NLEDVQPHDLGK, KGATRFK, EGKGFEP, LFGKRKYTYNYEAESSSKTTKQSFD, SVKAQYKKNKHMIS, GRTCPKPDDLPF, PLKTFYEPGEEIT, KPGYVSRGGMRK, RYTTFEYPNTIS, KCTEEGKWSPELP, KVPVKKA, YQGERVKIQEKFKNGM, FCKNKEKKCSYTEDAQ, PKCFKEH, WKTDASDVKP |
| Turns | DVANNTNEE |
| Exposed surface | SPKVTKD, IDLKDKYKNI, AELKKQSKPVT, MKKVGRKG, NTSKGQK, GDNRKNQLKDM, GKRKYTYNYE, SSKTTKQS, VKAQYKKNKHMI, PKPDDLP, KVPVKKA, ERVKIQEKFKNG, FCKNKEKKCSY |
| Polarity | KSIDLKDKYKNI, ARSIAKEGFEKI, NPVEIRRGVM, IAELKKQSKPV, AMKKVGRKG, DELEIIEGMKFDR, SKGQKCEF, LSEKKISSI, EIANAHRKPLVI, AEDVDGEA, GDNRKNQLKD, EDVQPHD, KGATRFKHLIE, LFGKRKYTYN, EAESSSK, VKAQYKKNKHMIS, FYEPGEEIT, SRGGMRKF, SAKCTEEGKWSPE, YQGERVKIQEKFKNGM, FFCKNKEKKCSYTE, EVPKCFKEHSSLA |
| Antigenic propensity | YISPYFI, YVLLSEKK, SSIQSIVP, HRKPLVII, LSTLVLNRLKVGLQVV, KVGEVIVT, HLIEIGL, QSFDLSV, HMISPVLILFSSFLCHV, LPFSTVVPLKTFY, ITYSCKPGYVS, RKFICPLTGLW, LKCTPRVCPF, SPELPVC, GSSCKVPVKK, DKVSFFCKN, TIEVPKCFKE |
Conformational B-cell epitopes from full length protein using DiscoTope server
| Epitope | Position |
|---|---|
| GLU, GLN, SER, TRP, GLY, SER, PRO | 3, 14, 1, 0, 5, 2, 7 |
| GLY | 1 |
| LYS, THR, LEU, ASN | 8, 0, 2, 2 |
| GLY | 4 |
| LYS | 0 |
| LEU, GLU, ALA, GLN, TYR, LYS, LYS | 6, 14, 13, 7, 8, 4, 5 |
| GLN | 1 |
| GLU, ARG | 1, 5 |
| LYS, GLY, PHE, GLU, PRO, THR, LEU, GLU, ALA, LEU, PHE, GLY, LYS, ARG, LYS | 13, 6, 22, 17, 6, 6, 19, 1, 3, 0, 16, 17, 0, 0, 10 |
| TYR, THR, TYR, ASN, TYR, GLU, ALA | 8, 15, 9, 9, 20, 20, 15 |
| GLU | 9 |
| ALA | 1 |
| ASP | 4 |
| LYS, PRO, CYS | 1, 0, 4 |
Prediction of T-cell epitope by CTLPred
| Peptide rank | Start position | Sequence | Score |
|---|---|---|---|
| 1 | 58 | TVLARSIAK | 1.000 |
| 2 | 380 | AGRTCPKPD | 1.000 |
| 3 | 410 | YSCKPGYVS | 0.990 |
The result of prediction for MHC-I epitopes
| MHC type | Start and end position |
|---|---|
| MHC-Db | 17-25, 73-81, 85-93, 121-129, 140-148, 150-158, 196-204, 226-234, 263-278, 355-374, 424-440 |
| MHC-Dd | 17-42, 52-60, 79-87, 104-112, 118-131, 134-142, 144-152, 162-170, 179-202, 206-214, 220-228, 246-259, 266-274, 278-291, 300-308, 314-334, 359-367, 382-390, 419-427, 430-438, 448-461, 478-486, 491-499, 501-516, 526-539, 560-568 |
| MHC-Kb | 26-34, 123-131, 140-148, 162-170, 178-187, 194-202, 221-229, 300-308, 354-362, 390-398, 400-408, 458-466, 567-575 |
| MHC-Kd | 17-27, 30-38, 85-93, 101-109, 140-154, 163-171, 179-192, 196-204, 263-273, 317-325, 355-377, 400-418, 424-438, 462-470, 475-483, 517-525, 551-559 |
| MHC-Kk | 17-34, 47-77, 79-93, 107-127, 146-165, 178-204, 206-229, 267-290, 294-309, 313-326, 335-343, 348-363, 371-379, 388-396, 400-410, 427-435, 451-469, 487-495, 517-534, 551-563, 570-578 |
| MHC-Ld | 11-19, 23-31, 77-85, 101-113, 152-160, 172-180, 199-207, 224-232, 238-246, 258-266, 297-305, 310-326, 340-348, 362-372, 384-401, 403-411, 417-425, 427-477, 499-507, 509-517, 533-542, 561-573 |
Prediction of MHC-II epitopes
| Rank | Position | Sequence | Score |
|---|---|---|---|
| 1 | 31 | YKNIGAKLV | 18.129 |
| 2 | 109 | IAQVATISA | 15.593 |
| 3 | 305 | FKHLIEIGL | 15.277 |
| 4 | 359 | NKHMISPVL | 15.012 |
| 5 | 155 | IEGMKFDRG | 14.484 |
| 6 | 376 | HVAIAGRTC | 13.579 |
| 7 | 254 | LKDMAIATG | 12.327 |
| 8 | 178 | CEFQDAYVL | 12.032 |
| 9 | 410 | YSCKPGYVS | 11.36 |
| 10 | 184 | YVLLSEKKI | 10.601 |
| 11 | 518 | YQGERVKIQ | 10.224 |
| 12 | 158 | MKFDRGYIS | 9.578 |
| 13 | 463 | YPNTISFSC | 8.695 |